US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,341.13

-8.1082-0.60%

Number of Gainers:7

Number of Losers:13

Number of Flat:- -

PE:- -

High:1,349.81

Open:1,349.81

Low:1,326.47

Close:1,349.23

Loading ...

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

FACTBOX-European companies cut jobs as economy slows

BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025

BRIEF-UK's MHRA Says Marstacimab Approved For Patients Aged 12 Years & Above With Haemophilia A Or B

UK's Mhra: Marstacimab Approved to Treat Patients Aged 12 Years and Above (Weighing at Least 35 Kg) With Haemophilia a or B

THOMSON REUTERS

Hutchmed Completes Patient Enrollment in Phase II Gastric Cancer Trial in China

MT Newswires Live

Goldman Sachs Remains a Buy on AstraZeneca (AZN)

EQ Resources Limited Appoints New Director

EQ Resources Strengthens Board with Industry Veteran Appointment

Why the Market Dipped But Novavax (NVAX) Gained Today

Cassava Sciences Chief Medical Officer Kupiec Retires

Press Release: Royalty Pharma Declares Second Quarter 2025 Dividend

Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders

European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading

MT Newswires Live

Pfizer : Bofa Global Research Cuts Price Objective to $26 From $29

THOMSON REUTERS

Johnson & Johnson to Present Latest Trial Data for TAR-200 to Treat Bladder Cancer

MT Newswires Live

Gilead reports ASCENT-04/KEYNOTE-D19 study met primary endpoint

Gilead ASCENT-04 data a ‘welcome surprise,’ says Oppenheimer

Johnson & Johnson announces new data from oncology pipeline at AUA meeting

Gilead Says Trodelvy-Keytruda Combination Improved Progression-Free Survival in Breast Cancer Study

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4568/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1341.1263,"timestamp":1745611199999,"preClose":1349.2345,"halted":0,"volume":105403296,"delay":0,"changeRate":-0.006009,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-8.108154,"latestTime":"04-25 16:00:00 EDT","open":1349.8055,"high":1349.8055,"low":1326.4735,"amount":5679459236.570498,"amplitude":0.017293,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745847000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.624317,"peRate":21.905145,"turnoverRate":0.006797,"increases":7,"decrements":13,"flats":0,"marketCap":1107563323728.5,"floatMarketCap":1088066496974.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1349.8055,"amplitude":0.017293,"preClose":1349.2345,"low":1326.4735,"pbRate":"3.624317","latestPrice":1341.1263,"volume":105403296,"delay":0,"open":1349.8055,"prevYearClose":1274.8187,"prevWeekClose":1341.1263,"prevMonthClose":1427.887,"prevQuarterClose":1427.887,"fiveDayClose":1341.7848,"twentyDayClose":1413.7192,"sixtyDayClose":1349.6512,"secType":"PLATE","market":"US","turnoverRate":0.006797,"peRate":21.905145,"marketCap":1107563323728.5,"floatMarketCap":1088066496974.5,"timestamp":1745611199999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":7,"down":13,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529884085","title":"iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio","url":"https://stock-news.laohu8.com/highlight/detail?id=2529884085","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529884085?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:00","pubTimestamp":1745323200,"startTime":"0","endTime":"0","summary":"In-Licensing of novel activin E antibody underscores iBio’s commitment to delivering meaningful benefits to patients living with obesity and cardiometabolic diseases. “Our decision to license this Activin E-targeting functional antibody, a potentially first-in-class molecule, at this early stage reflects our firm belief in Activin E as a promising therapeutic target and our confidence in building upon the strong preclinical data we recently published,” said Martin Brenner, Ph.D., DVM, iBio’s Chief Executive Officer and Chief Scientific Officer. “This antibody represents a strategic expansion of our pipeline in cardiometabolic diseases and obesity and a significant step toward clinical development of a medi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ibio-expands-cardiometabolic-obesity-pipeline-120000559.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","IBIO","BK4139"],"gpt_icon":0},{"id":"2529379416","title":"FACTBOX-European companies cut jobs as economy slows","url":"https://stock-news.laohu8.com/highlight/detail?id=2529379416","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529379416?lang=en_us&edition=fundamental","pubTime":"2025-04-22 18:53","pubTimestamp":1745319231,"startTime":"0","endTime":"0","summary":"FACTBOX-European companies cut jobs as economy slowsAdds Stellantis, Volvo, Deutsche Bank, UBS, Morrisons and Nestle; changes cut-off period to March","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nL8N3R00FN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","BK4585","BNTX","BK4548","BK4551","BK4535","BK4588"],"gpt_icon":0},{"id":"2529722603","title":"BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529722603","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529722603?lang=en_us&edition=fundamental","pubTime":"2025-04-22 18:45","pubTimestamp":1745318700,"startTime":"0","endTime":"0","summary":"MAINZ, Germany, April 22, 2025  --BioNTech SE  will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT  for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link.Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at www.BioNTech.com. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biontech-report-first-quarter-2025-104500441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4535","CAR","BK4585","BK4022","BK4588","BK4568","BNTX","BK4551","BK4230","BK4139","BK4548"],"gpt_icon":0},{"id":"2529533378","title":"BRIEF-UK's MHRA Says Marstacimab Approved For Patients Aged 12 Years & Above With Haemophilia A Or B","url":"https://stock-news.laohu8.com/highlight/detail?id=2529533378","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529533378?lang=en_us&edition=fundamental","pubTime":"2025-04-22 18:12","pubTimestamp":1745316769,"startTime":"0","endTime":"0","summary":"BRIEF-UK's MHRA Says Marstacimab Approved For Patients Aged 12 Years & Above With Haemophilia A Or BApril 22  - UK'S MHRA: UK'S MHRA: MARSTACIMAB APPROVED TO TREAT PATIENTS AGED 12 YEARS AND ABOVE  WITH HAEMOPHILIA A OR BFurther company coverage: PFE.N ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nFWN3R00VL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B19Z3B42.SGD","LU0122379950.USD","BK4585","BK4533","IE00BLSP4452.SGD","LU0234572021.USD","SG9999001176.USD","LU0170899867.USD","BK4550","LU0985481810.HKD","LU1883839398.USD","IE000M9KFDE8.USD","LU0456855351.SGD","SG9999011175.SGD","LU1066053197.SGD","IE00B19Z3581.USD","LU1066051498.USD","LU0306806265.USD","SG9999002232.USD","LU1023059063.AUD","LU1057294990.SGD","BK4534","BK4592","LU0225771236.USD","SGXZ57979304.SGD","SG9999003800.SGD","IE00BLSP4239.USD","BK4599","BK4581","IE00BBT3K403.USD","LU0225284248.USD","SG9999001176.SGD","LU0058720904.USD","LU1894683348.USD","PFE","LU0306807586.USD","LU0321505868.SGD","BK4007","LU0321505439.SGD","SG9999013999.USD","SG9999002224.SGD","BK4568","IE0002270589.USD","LU0868494617.USD","LU0289739699.SGD","LU1894683264.USD"],"gpt_icon":0},{"id":"2529378358","title":"UK's Mhra: Marstacimab Approved to Treat Patients Aged 12 Years and Above (Weighing at Least 35 Kg) With Haemophilia a or B","url":"https://stock-news.laohu8.com/highlight/detail?id=2529378358","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529378358?lang=en_us&edition=fundamental","pubTime":"2025-04-22 18:11","pubTimestamp":1745316669,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nFWN3R00VL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1894683264.USD","LU1894683348.USD","LU0306806265.USD","LU0170899867.USD","LU0456855351.SGD","LU0225771236.USD","LU0306807586.USD","LU0289739699.SGD","LU0321505868.SGD","LU0321505439.SGD","LU1883839398.USD","BK4568","BK4592","LU1057294990.SGD","LU1066051498.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","SG9999001176.SGD","LU0234572021.USD","LU1023059063.AUD","SG9999003800.SGD","IE00BLSP4239.USD","IE0002270589.USD","LU0985481810.HKD","BK4588","LU0058720904.USD","IE00BLSP4452.SGD","BK4007","BK4599","BK4533","PFE","LU0122379950.USD","LU0868494617.USD","SG9999002224.SGD","LU0225284248.USD","IE00B19Z3B42.SGD","SG9999002232.USD","BK4581","SG9999013999.USD","BK4550","SG9999001176.USD","BK4534","SGXZ57979304.SGD","LU1066053197.SGD","IE00BBT3K403.USD","BK4585","SG9999011175.SGD"],"gpt_icon":0},{"id":"2529340744","title":"Hutchmed Completes Patient Enrollment in Phase II Gastric Cancer Trial in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2529340744","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529340744?lang=en_us&edition=fundamental","pubTime":"2025-04-22 16:43","pubTimestamp":1745311386,"startTime":"0","endTime":"0","summary":"Hutchmed   said late Monday it completed enrollment in the registration phase of a phase II trial to assess the efficacy, safety and tolerability of savolitinib in gastric cancer patients with MET amplification.A total of 64 patients have been enrolled in the trial.If positive, the company may begin plans to apply for marketing authorization of savolitinib for gastric cancer in China later this year, it said.Savolitinib is being jointly developed by AstraZeneca  and Hutchmed, and commercialized by AstraZeneca.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0109394709.USD","BK4531","BK4585","LU2236285917.USD","BK4588","BK1587","BK4568","LU2417539215.USD","LU0320765992.SGD","00013","LU2462157665.USD","BK4007","LU0889565916.HKD","LU2456880835.USD","AZN","BK1191","LU1829250122.USD","HCM","BK1588"],"gpt_icon":0},{"id":"2529496193","title":"Goldman Sachs Remains a Buy on AstraZeneca (AZN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2529496193","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529496193?lang=en_us&edition=fundamental","pubTime":"2025-04-22 15:56","pubTimestamp":1745308606,"startTime":"0","endTime":"0","summary":"In a report released today, Rajan Sharma from Goldman Sachs maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/goldman-sachs-remains-a-buy-on-astrazeneca-azn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/goldman-sachs-remains-a-buy-on-astrazeneca-azn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2237443978.SGD","IE0004091025.USD","BK4533","LU2471134796.USD","LU1829250122.USD","LU2237443622.USD","LU2471134879.HKD","IE0034235188.USD","LU0106831901.USD","LU2237443549.SGD","LU2750360641.GBP","LU1868836757.USD","LU2237443382.USD","LU2471134523.USD","IE00BFXG1179.USD","LU2417539215.USD","BK4516","BK4568","LU0109394709.USD","LU0061475181.USD","LU0251131958.USD","BK4007","LU0096364046.USD","LU2456880835.USD","LU2237443465.HKD","LU2237443895.HKD","AZN","BK4127","IE0002270589.USD","IE0004086264.USD","LU0048573561.USD","LU1868837300.USD","BK4552","BK4588","LU1868836914.USD","IE00BSNM7G36.USD","BK4504","LU0251142724.SGD","LU2471134952.CNY","IE00B19Z3581.USD","LU2237438978.USD","LU1668664300.SGD","LU1868836591.USD","LU2462157665.USD","BK4585","LU2236285917.USD","LU0742534661.SGD","IE00B19Z3B42.SGD","LU2750360997.AUD","BK4550"],"gpt_icon":0},{"id":"2529396998","title":"EQ Resources Limited Appoints New Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2529396998","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529396998?lang=en_us&edition=fundamental","pubTime":"2025-04-22 10:47","pubTimestamp":1745290041,"startTime":"0","endTime":"0","summary":"The latest announcement is out from EQ Resources Limited ( ($AU:EQR) ). EQ Resources Limited has announced the appointment of Mr. Craig Richard Bra...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eq-resources-limited-appoints-new-director?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eq-resources-limited-appoints-new-director?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4568","EQ"],"gpt_icon":0},{"id":"2529652773","title":"EQ Resources Strengthens Board with Industry Veteran Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2529652773","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529652773?lang=en_us&edition=fundamental","pubTime":"2025-04-22 08:27","pubTimestamp":1745281634,"startTime":"0","endTime":"0","summary":"An update from EQ Resources Limited ( ($AU:EQR) ) is now available. EQ Resources Limited has appointed Craig Bradshaw, a veteran in the tungsten in...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eq-resources-strengthens-board-with-industry-veteran-appointment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eq-resources-strengthens-board-with-industry-veteran-appointment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","EQ","BK4139"],"gpt_icon":0},{"id":"2529571823","title":"Why the Market Dipped But Novavax (NVAX) Gained Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2529571823","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529571823?lang=en_us&edition=fundamental","pubTime":"2025-04-22 05:45","pubTimestamp":1745271930,"startTime":"0","endTime":"0","summary":"Novavax  closed the most recent trading day at $6.01, moving +0.17% from the previous trading session. This change outpaced the S&P 500's 2.36% loss on the day. Elsewhere, the Dow saw a downswing of 2.48%, while the tech-heavy Nasdaq depreciated by 2.55%.Prior to today's trading, shares of the vaccine maker had lost 21.05% over the past month. This has lagged the Medical sector's loss of 9.83% and the S&P 500's loss of 5.6% in that time.Analysts and investors alike will be keeping a close eye on the performance of Novavax in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $0.19, marking a 118.1% rise compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $71.84 million, down 23.47% from the year-ago period.The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-market-dipped-novavax-nvax-214530987.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4585","BK4568","NVAX","BK4547","BK4139"],"gpt_icon":0},{"id":"2529356819","title":"Cassava Sciences Chief Medical Officer Kupiec Retires","url":"https://stock-news.laohu8.com/highlight/detail?id=2529356819","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529356819?lang=en_us&edition=fundamental","pubTime":"2025-04-22 05:17","pubTimestamp":1745270220,"startTime":"0","endTime":"0","summary":"Cassava Sciences said its chief medical officer, Dr. James Kupiec, is retiring, effective May 9.Under Kupiec, the clinical-stage biotechnology company completed a clinical trial program in Alzheimer's disease drug development. Kupiec has been chief medical officer since December 2022 following a stint as Cassava's chief clinical development officer. He previously worked at Pfizer.Cassava on Monday also said it appointed Jack Moore as senior vice president of clinical development. Moore was most recently the head of global medical affairs at Alector, and also worked at Janssen Pharmaceutica, Novartis Pharmaceuticals, and Celgene.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4588","LU0122379950.USD","BK4547","LU1066051498.USD","IE00BLSP4452.SGD","LU1066053197.SGD","BK4568","LU1894683264.USD","LU0985481810.HKD","SGXZ57979304.SGD","BK4581","IE00BBT3K403.USD","LU1057294990.SGD","LU0225284248.USD","SG9999001176.USD","IE0002270589.USD","LU1883839398.USD","LU0225771236.USD","LU0868494617.USD","SG9999013999.USD","SG9999002224.SGD","LU0170899867.USD","BK4585","LU0234572021.USD","BK4533","LU0321505868.SGD","BK4550","SG9999011175.SGD","SAVA","LU0306807586.USD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","LU1023059063.AUD","LU0058720904.USD","BK4592","LU0321505439.SGD","SG9999001176.SGD","IE000M9KFDE8.USD","LU0306806265.USD","LU0289739699.SGD","BK4007","BK4599","LU1894683348.USD","SG9999003800.SGD","SG9999002232.USD","LU0456855351.SGD","IE00B19Z3581.USD"],"gpt_icon":1},{"id":"2529309223","title":"Press Release: Royalty Pharma Declares Second Quarter 2025 Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2529309223","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529309223?lang=en_us&edition=fundamental","pubTime":"2025-04-22 04:15","pubTimestamp":1745266500,"startTime":"0","endTime":"0","summary":"NEW YORK, April 21, 2025  -- The board of directors of Royalty Pharma plc  has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share.The dividend will be paid on June 10, 2025, to shareholders of record at the close of business on May 16, 2025.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683264.USD","LU1894683348.USD","LU0306806265.USD","LU0170899867.USD","LU0456855351.SGD","RPRX","LU0225771236.USD","LU0306807586.USD","LU0289739699.SGD","LU0321505868.SGD","LU0321505439.SGD","LU1883839398.USD","BK4568","BK4592","LU1057294990.SGD","LU1066051498.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","SG9999001176.SGD","LU0234572021.USD","LU1023059063.AUD","SG9999003800.SGD","IE00BLSP4239.USD","IE0002270589.USD","LU0985481810.HKD","BK4588","LU0058720904.USD","IE00BLSP4452.SGD","BK4007","BK4599","BK4533","LU0122379950.USD","LU0868494617.USD","SG9999002224.SGD","LU0225284248.USD","IE00B19Z3B42.SGD","SG9999002232.USD","BK4581","SG9999013999.USD","BK4550","SG9999001176.USD","BK4534","SGXZ57979304.SGD","LU1066053197.SGD","IE00BBT3K403.USD","BK4585","SG9999011175.SGD"],"gpt_icon":1},{"id":"2529033021","title":"Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2529033021","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529033021?lang=en_us&edition=fundamental","pubTime":"2025-04-22 04:05","pubTimestamp":1745265900,"startTime":"0","endTime":"0","summary":"Believes Company’s Misguided Acquisition Strategy is Destroying Value and Preventing Dynavax from Maximizing the Opportunities of Heplisav for Shareholders and Patients. In Deep Track’s View, Properly Focusing on Heplisav Could Result in More than $1 Billion in Cash Generation by 2030 – More than Dynavax’s Current Enterprise Value. Sees Shareholder Representation on Board as Necessary to Restore Investor Confidence in Dynavax and Prevent Strategic Blunders. GREENWICH, Conn., April 21, 2025----Deep Track Capital, LP, , one of the largest shareholders of Dynavax Technologies Corporation  , with ownership of approximately 14.53% of the Company’s outstanding shares, today announced that it has filed a definitive proxy statement in connection with its nomination of four highly qualified candidates for election to the Company’s Board of Directors  at the 2025 Annual Meeting of Stockholders . Deep Track also sent a letter to shareholders.We are not a typical \"activist\" investor. We are a long","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/deep-track-capital-files-definitive-200500490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4551","SNY","TARS","GBT","MNQmain","BK4023","PSQ","SQQQ","BK4139","BK4596","NVIW.SI","BK4568","BK4595","USJW.SI","MRNA","USAW.SI","DVAX","IE00BFXG1179.USD","NQmain","BK4585","BK4532","TQQQ","BK4534","QLD","BK4007","TSYW.SI",".IXIC","QID","BK4501","BK4533","STRK","BK4600","BK4516","BK4588","BK4548"],"gpt_icon":1},{"id":"2529644386","title":"European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2529644386","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529644386?lang=en_us&edition=fundamental","pubTime":"2025-04-21 23:01","pubTimestamp":1745247715,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts kicked off the week on a down note Monday morning, falling 0.87% to 1,321.99 on the S&P Europe Select ADR Index.From continental Euro","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4115","BK4551","NCNA","EDAP","BK4585","BK4139","TEF","BK4007","BK4141","BNTX","BK4548","CUK","BK4535","AFG","AUTL","BK4117","BK4568","BK4554","BK4515","ERIC","BK4107","BK4020","BK4505","ADAP","VRNA","TRIB","MREO","BK4546","BK4077","MTLS","OPRA","BK4591","SLN","TRVG","SQNS","BK4023","BK4588","BK4142","BK4082"],"gpt_icon":0},{"id":"2529238598","title":"Pfizer : Bofa Global Research Cuts Price Objective to $26 From $29","url":"https://stock-news.laohu8.com/highlight/detail?id=2529238598","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529238598?lang=en_us&edition=fundamental","pubTime":"2025-04-21 22:53","pubTimestamp":1745247183,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nFWN3QZ1OM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0321505439.SGD","IE00B19Z3581.USD","IE00BBT3K403.USD","IE000M9KFDE8.USD","LU0058720904.USD","LU1023059063.AUD","IE00B19Z3B42.SGD","SG9999013999.USD","SG9999003800.SGD","LU1894683264.USD","BK4550","LU0289739699.SGD","LU0321505868.SGD","LU0170899867.USD","SG9999002232.USD","BK4581","BK4007","LU0225284248.USD","PFE","LU0234572021.USD","BK4592","BK4534","BK4585","LU0225771236.USD","LU0306807586.USD","LU1883839398.USD","IE0002270589.USD","LU0306806265.USD","LU0456855351.SGD","SGXZ57979304.SGD","SG9999001176.USD","LU1057294990.SGD","SG9999002224.SGD","SG9999011175.SGD","IE00BLSP4452.SGD","SG9999001176.SGD","BK4599","LU0122379950.USD","IE00BLSP4239.USD","LU0985481810.HKD","BK4568","LU0868494617.USD","LU1066053197.SGD","LU1894683348.USD","LU1066051498.USD","BK4533","BK4588"],"gpt_icon":0},{"id":"2529385341","title":"Johnson & Johnson to Present Latest Trial Data for TAR-200 to Treat Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529385341","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529385341?lang=en_us&edition=fundamental","pubTime":"2025-04-21 22:45","pubTimestamp":1745246730,"startTime":"0","endTime":"0","summary":"Johnson & Johnson  said Monday it will present the latest data from the TAR-200 study to treat patients with Bacillus Calmette-Guerin-unresponsive, high-risk non-muscle-invasive bladder cancer with carcinoma in situ with or without papillary disease at the American Urological Association on April 26.The 12-month duration of response findings from cohort 2 of the phase 2b trial evaluating the TAR-200 monotherapy revealed a positive complete response rate, according to a statement.The company said it will also present the first results from cohort 4 of the phase 2b trial for patients with papillary-only, high-risk non-muscle invasive bladder cancer.Price: 157.83, Change: +0.35, Percent Change: +0.23","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1244550221.USD","BK4504","LU1430594728.SGD","IE00BJT1NW94.SGD","LU1162221912.USD","LU1023059063.AUD","LU2430703095.HKD","BK4568","IE00B19Z3B42.SGD","LU1061106388.HKD","IE00BSNM7G36.USD","JNJ","LU1059921491.USD","LU1506573853.SGD","LU0889566641.SGD","LU1066051498.USD","BK4585","LU0345769631.USD","LU2592432038.USD","SG9999001440.SGD","BK4588","LU0203347892.USD","LU1267930813.SGD","LU0345770308.USD","LU1074936037.SGD","BK4534","LU1280957306.USD","LU0345770993.USD","LU2430703251.USD","IE00BVYPNW00.USD","IE00BDGV0183.EUR","LU1032955483.USD","IE0002270589.USD","LU1032466523.USD","BK4007","LU1894683264.USD","IE00B3T34201.USD","LU0912757837.SGD","LU1894683348.USD","LU0058720904.USD","BK4550","LU0320765646.SGD","IE00BN8TJ469.HKD","LU0795875169.SGD","LU1221951046.USD","LU1066051811.HKD","LU1674673428.USD","LU0466842654.USD","LU1196500208.SGD","LU0234570918.USD"],"gpt_icon":0},{"id":"2529800286","title":"Gilead reports ASCENT-04/KEYNOTE-D19 study met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2529800286","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529800286?lang=en_us&edition=fundamental","pubTime":"2025-04-21 22:15","pubTimestamp":1745244937,"startTime":"0","endTime":"0","summary":"Gilead Sciences (GILD) announced topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy plus Keytruda significan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-reports-ascent-04-keynote-d19-study-met-primary-endpoint?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-reports-ascent-04-keynote-d19-study-met-primary-endpoint?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0965509283.SGD","LU1941712264.USD","LU2361044865.SGD","GILD","LU1989772840.SGD","LU1035773651.USD","IE0002141913.USD","LU1585245621.USD","IE00B7SZLL34.SGD","SG9999014575.USD","BK4578","LU0861579265.USD","LU1934455277.USD","BK4568","LU1066051225.USD","LU1066051811.HKD","BK4583","IE00B2B36J28.USD","LU1093756325.SGD","LU0234572021.USD","BK4550","LU0965509101.SGD","BK4534","LU0006306889.USD","LU1917777945.USD","LU1941712348.USD","SG9999002232.USD","BK4516","LU1571399168.USD","LU1116320901.HKD","LU0289739699.SGD","IE00BLSP4239.USD","LU0058720904.USD","BK4585","IE00B1BXHZ80.USD","LU1430594728.SGD","SG9999001440.SGD","LU1116320737.USD","SG9999001176.USD","MRK","LU0265550359.USD","LU1983299246.USD","LU2468319806.SGD","IE00B19Z3B42.SGD","LU0266013472.USD","LU1023059063.AUD","LU0109394709.USD","SG9999002224.SGD","LU2112291526.USD","LU1061106388.HKD"],"gpt_icon":0},{"id":"2529800281","title":"Gilead ASCENT-04 data a ‘welcome surprise,’ says Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529800281","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529800281?lang=en_us&edition=fundamental","pubTime":"2025-04-21 22:15","pubTimestamp":1745244927,"startTime":"0","endTime":"0","summary":"Oppenheimer says Gilead (GILD) provided a “welcome surprise” this morning with ASCENT-04 hitting its primary endpoint. The firm was not expecting t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-ascent-04-data-a-welcome-surprise-says-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-ascent-04-data-a-welcome-surprise-says-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4568","BK4532","LU1571399168.USD","IE00B3T34201.USD","LU0109394709.USD","LU0289739699.SGD","IE00B19Z3581.USD","IE00BKVL7J92.USD","OPY","BK4588","LU0320765992.SGD","IE00B7SZLL34.SGD","LU1585245621.USD","BK4578","LU1066053197.SGD","GILD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","IE00BZ1G4Q59.USD","LU2468319806.SGD","LU2089984988.USD","BK4585","LU1066051498.USD","BK4127","LU1839511570.USD","BK4583","LU0889565916.HKD","IE0002270589.USD","LU0058720904.USD","LU0234570918.USD","LU1430594728.SGD","BK4566","LU2087621335.USD","BK4550"],"gpt_icon":0},{"id":"2529807518","title":"Johnson & Johnson announces new data from oncology pipeline at AUA meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2529807518","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529807518?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:56","pubTimestamp":1745243807,"startTime":"0","endTime":"0","summary":"Johnson & Johnson announced that new data from its oncology pipeline will be presented at the American Urological Association 2025 Annual Meeting, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/johnson-johnson-announces-new-data-from-oncology-pipeline-at-aua-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/johnson-johnson-announces-new-data-from-oncology-pipeline-at-aua-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IE00B19Z3B42.SGD","JNJ","IE00BJJMRZ35.SGD","LU1032466523.USD","IE00B3T34201.USD","LU1929549753.HKD","LU2430703095.HKD","LU0234570918.USD","IE00B42XCP33.USD","LU1066051225.USD","LU2347655156.SGD","LU0345769631.USD","LU0234572021.USD","LU1074936037.SGD","LU0203345920.USD","LU0985320562.USD","IE00BDGV0183.EUR","LU1244550221.USD","LU1162221912.USD","LU2129689514.USD","LU1066053197.SGD","BK4532","IE00B2B36J28.USD","SG9999001440.SGD","LU1280957306.USD","LU1244550577.SGD","LU1585245621.USD","LU0912757837.SGD","LU0114720955.EUR","LU0320765646.SGD","IE00BN8TJ469.HKD","LU1261432733.SGD","IE00BLSP4239.USD","LU1221951129.SGD","IE00BGHQF631.EUR","IE00BVYPNV92.GBP","LU1894683348.USD","LU1718418525.SGD","LU1430594728.SGD","LU0098860793.USD","SG9999002224.SGD","BK4568","LU0792757196.USD","LU2112291526.USD","LU1674673691.USD","LU0345770308.USD","LU0889566641.SGD","LU2133065610.SGD","LU0345769128.USD"],"gpt_icon":0},{"id":"2529804157","title":"Gilead Says Trodelvy-Keytruda Combination Improved Progression-Free Survival in Breast Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2529804157","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529804157?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:37","pubTimestamp":1745242672,"startTime":"0","endTime":"0","summary":"Gilead Sciences  said Monday that a phase 3 breast cancer study met its primary endpoint, showing that Trodelvy plus Keytruda \"significantly\" improved progression-free survival compared with Keytruda and chemotherapy.The safety profile of the Trodelvy-Keytruda combination also showed consistency with the know safety profile of each agent, Gilead said.The company said overall survival is a key secondary endpoint and was not mature during the progression-free survival analysis, but there was an early trend in improved overall survival with the combination.Merck  and Gilead entered into a collaboration in 2021 to evaluate the Trodelvy-Keytruda combination compared to Keytruda plus chemotherapy in patients with previously untreated, inoperable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1, Gilead said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0965509101.SGD","SG9999001440.SGD","LU1057294990.SGD","IE00B4R5TH58.HKD","LU1571399168.USD","IE00BKVL7J92.USD","LU1037948541.HKD","SG9999002224.SGD","BK4568","IE00BLSP4452.SGD","LU0106261372.USD","LU0985320562.USD","LU0122379950.USD","LU1934455194.USD","BK4550","IE00B19Z3B42.SGD","GILD","LU0320765646.SGD","LU1941712348.USD","LU1929549753.HKD","IE00B2B36J28.USD","LU1116320737.USD","LU2023250843.SGD","IE00B3T34201.USD","LU0320765489.SGD","LU1066051225.USD","BK4566","SG9999001176.USD","IE0002270589.USD","LU0965509283.SGD","LU0109394709.USD","SG9999013999.USD","LU0320765992.SGD","LU2324357040.USD","SG9999014567.USD","LU1023059063.AUD","MRK","BK4516","IE00BZ1G4Q59.USD","LU2106854487.HKD","LU1983299246.USD","SG9999015358.SGD","IE00B7SZLL34.SGD","LU2023250504.SGD","LU0889565916.HKD","SGXZ57979304.SGD","BK4588","LU1699723380.USD","LU0861579265.USD","LU0203345920.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":7,"totalSize":293,"code":"91000000","status":"200"}]}}